Last reviewed 2026-04-22 · How we verify

Etanercept via Autoinjector B

Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.

Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Ankylosing spondylitis.

At a glance

Mechanism of action

Etanercept consists of the extracellular ligand-binding portion of the human TNF receptor fused to the Fc region of human IgG1. It acts as a soluble TNF receptor that competitively inhibits TNF-α and TNF-β from binding to cell surface TNF receptors, thereby suppressing TNF-mediated inflammatory responses. This mechanism reduces inflammation and immune activation in autoimmune and inflammatory conditions.

Approved indications

• Rheumatoid arthritis
• Polyarticular juvenile idiopathic arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Plaque psoriasis
• Crohn's disease

Common side effects

• Injection site reactions
• Upper respiratory tract infections
• Headache
• Serious infections
• Tuberculosis reactivation

Key clinical trials

• Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Etanercept via Autoinjector B CI brief — competitive landscape report
• Etanercept via Autoinjector B updates RSS · CI watch RSS
• Amgen portfolio CI